Compare AUID & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | COCP |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 15.6M |
| IPO Year | 2014 | 2011 |
| Metric | AUID | COCP |
|---|---|---|
| Price | $1.23 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 158.3K | ★ 196.1K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | $2,040,660.00 | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.20 | N/A |
| 52 Week Low | $0.84 | $0.86 |
| 52 Week High | $5.82 | $2.19 |
| Indicator | AUID | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 46.47 |
| Support Level | $1.16 | $1.28 |
| Resistance Level | $1.42 | $1.42 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 31.44 | 13.59 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).